procetofen

Summary

Summary: An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.

Top Publications

  1. ncbi Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients
    Nuria Roglans
    Pharmacology Unit, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain
    Eur J Clin Pharmacol 59:855-61. 2004
  2. ncbi PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages
    B P Neve
    , U.325 INSERM, Institut Pasteur de Lille, , , France
    Circulation 103:207-12. 2001
  3. ncbi Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis
    Philip J Larsen
    Rheoscience, Rødovre, Denmark
    Diabetes 52:2249-59. 2003
  4. ncbi Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats
    H J Lee
    Department of Pharmacology, Dong A University College of Medicine, Busan, Republic of Korea
    Biochem Biophys Res Commun 296:293-9. 2002
  5. ncbi Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway
    Jaetaek Kim
    Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Chung Ang University, 224 1 Heuk Seok dong, Dongjak Ku, Seoul 156 755, South Korea
    Exp Eye Res 84:886-93. 2007
  6. ncbi Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation
    Eun Hee Koh
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea
    Diabetes 52:2331-7. 2003
  7. ncbi Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
    A C Keech
    NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
    Lancet 370:1687-97. 2007
  8. ncbi Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators
    Ngoc Vu-Dac
    Departement d Atherosclerose, U 545 INSERM, Institut Pasteur de Lille and Faculté de Pharmacie de Lille, 1 rue Calmette BP 245, 59019 Lille Cedex, France
    J Biol Chem 278:17982-5. 2003
  9. ncbi Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia
    Kwang Kon Koh
    Department of Cardiology, Gachon Medical School, Incheon, Korea
    J Am Coll Cardiol 45:1649-53. 2005
  10. ncbi Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with
    Takehiro Ogata
    Cardiovascular Division, Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    J Am Coll Cardiol 43:1481-8. 2004

Detail Information

Publications191 found, 100 shown here

  1. ncbi Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients
    Nuria Roglans
    Pharmacology Unit, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain
    Eur J Clin Pharmacol 59:855-61. 2004
    ....
  2. ncbi PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages
    B P Neve
    , U.325 INSERM, Institut Pasteur de Lille, , , France
    Circulation 103:207-12. 2001
    ..Our results suggest a novel role for PPARalpha in the control of atherosclerotic plaque thrombogenicity through its effects on TF expression in monocytes and macrophages...
  3. ncbi Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis
    Philip J Larsen
    Rheoscience, Rødovre, Denmark
    Diabetes 52:2249-59. 2003
    ....
  4. ncbi Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats
    H J Lee
    Department of Pharmacology, Dong A University College of Medicine, Busan, Republic of Korea
    Biochem Biophys Res Commun 296:293-9. 2002
    ..It might result in reduction of adiposity of truncal adipose tissue and skeletal muscle. We suggest that reduction of adiposity in trunk and skeletal muscle might improve insulin sensitivity...
  5. ncbi Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway
    Jaetaek Kim
    Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Chung Ang University, 224 1 Heuk Seok dong, Dongjak Ku, Seoul 156 755, South Korea
    Exp Eye Res 84:886-93. 2007
    ..Thus fenofibrate may have a novel therapeutic property that can control unwanted cell death found in diabetic retinopathy...
  6. ncbi Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation
    Eun Hee Koh
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea
    Diabetes 52:2331-7. 2003
    ....
  7. ncbi Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
    A C Keech
    NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
    Lancet 370:1687-97. 2007
    ..Our aim was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce the progression of retinopathy and the need for laser treatment in patients with type 2 diabetes mellitus...
  8. ncbi Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators
    Ngoc Vu-Dac
    Departement d Atherosclerose, U 545 INSERM, Institut Pasteur de Lille and Faculté de Pharmacie de Lille, 1 rue Calmette BP 245, 59019 Lille Cedex, France
    J Biol Chem 278:17982-5. 2003
    ..These findings demonstrate that APOA5 is a highly responsive peroxisome proliferator-activated receptor alpha target gene and support its role as a major mediator for how fibrates reduce plasma triglycerides in humans...
  9. ncbi Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia
    Kwang Kon Koh
    Department of Cardiology, Gachon Medical School, Incheon, Korea
    J Am Coll Cardiol 45:1649-53. 2005
    ..We compared vascular and metabolic responses (and adverse responses) to statin and fibrate therapies alone or in combination in patients with combined hyperlipidemia...
  10. ncbi Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with
    Takehiro Ogata
    Cardiovascular Division, Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    J Am Coll Cardiol 43:1481-8. 2004
    ....
  11. ncbi Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia
    Vasilios G Athyros
    Lipid Out patient Clinic, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Diabetes Care 25:1198-202. 2002
    ..This study evaluated the effect of a atorvastatin-fenofibrate combination on lipid profile, in comparison to each drug alone, in patients with type 2 diabetes and combined hyperlipidemia (CHL)...
  12. ncbi Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Domino s Farms, 24 Frank Lloyd Wright Dr, Lobby A, Ann Arbor, MI 48106 0736, USA
    Diabetes Care 30:1945-51. 2007
    ..The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome...
  13. ncbi Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats
    F P Mancini
    , Fisiche e Naturali, , Via Port'Arsa 11, 82100 Benevento, Italy
    FEBS Lett 491:154-8. 2001
    ..Finally, FF lowered mRNA levels of uncoupling protein-2 and did not affect mitochondrial respiration in skeletal muscle. Therefore, FF seems to act as a weight-stabilizer mainly through its effect on liver metabolism...
  14. ncbi Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
    A Keech
    Lancet 366:1849-61. 2005
    ..We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients...
  15. ncbi Fenofibrate potentiates warfarin effects
    Karissa Y Kim
    Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA 19140 5101, USA
    Ann Pharmacother 37:212-5. 2003
    ..To describe 2 patients in whom the initiation of fenofibrate potentiated warfarin's anticoagulant effects...
  16. ncbi PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats
    Quy N Diep
    Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, 110 Pine Avenue West, Montreal, Que, Canada H2W 1R7
    J Mol Cell Cardiol 36:295-304. 2004
    ..We tested the hypothesis that the PPAR alpha activator fenofibrate prevents myocardial inflammation and fibrosis in angiotensin (Ang) II-infused rats...
  17. ncbi A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions
    Pol Henri Guivarc'h
    SkyePharma Inc, Montreal, Quebec, Canada
    Clin Ther 26:1456-69. 2004
    ..Insoluble Drug Delivery-Microparticle (IDD-P) fenofibrate 160-mg tablets are a new formulation developed to provide bioavailability independent of food...
  18. ncbi Fenofibrate monotherapy induced rhabdomyolysis
    Billie J Barker
    Diabetes Care 26:2482-3. 2003
  19. ncbi Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice
    Trinity Vera
    Department of Physiology and Biophysics, for Excellence in Cardiovascular Renal Research, University of Mississippi Medical Center, Jackson, MS 39216 4505, USA
    Hypertension 45:730-5. 2005
    ..These results suggest that upregulation of the production of 20-HETE in renal tubules may contribute to the blood pressure-lowering effects of FF treatment in Ang II-dependent hypertension in C57BL/6J mice...
  20. ncbi Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control
    Elisabeth Cavallero
    Service de Medecine Interne, Nutrition, Métabolisme lipidique, CHU Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Atherosclerosis 166:151-61. 2003
    ..Diabetes control was unchanged throughout the study. Fenofibrate normalized the abnormal PP response and improved the fasting lipoprotein abnormalities in patients with type 2 diabetes and optimal glucose control...
  21. ncbi Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia
    T C Ooi
    Metabolism and Hormone Laboratory, Division of Endocrinology and Metabolism, Department of Medicine, Ottawa Hospital, University of Ottawa, Civic Campus, 1053 Carling Avenue, Ottawa, Ont, Canada K1Y 4E9
    Atherosclerosis 172:375-82. 2004
    ..These results indicate that fibrates are effective agents in reducing the postprandial increase in remnant lipoprotein particles...
  22. ncbi Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans
    Arthur J Bergman
    Merck Research Laboratories, WP75 100, Sumneytown Pike, West Point, PA 19486, USA
    J Clin Pharmacol 44:1054-62. 2004
    ..70, 1.43), no clinically significant pharmacokinetic drug interaction between fenofibrate and simvastatin was concluded in humans. The coadministration of simvastatin and fenofibrate in this study was well tolerated...
  23. ncbi PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice
    C W Park
    Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Kidney Int 69:1511-7. 2006
    ..The activation of PPARalpha by fenofibrate in mesangial cells may partially contribute to its renal protection. Thus, fenofibrate may serve as a therapeutic agent for type II diabetes and diabetic nephropathy...
  24. ncbi Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus
    Gillian M Keating
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 67:121-53. 2007
    ..Thus, fenofibrate is a valuable lipid-lowering agent, particularly in patients with atherogenic dyslipidaemia...
  25. ncbi The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia
    Ali Saklamaz
    Division of Endocrinology, Dokuz Eylul University Medical School, Inciralti, Izmir 35340, Turkey
    Metabolism 54:677-81. 2005
    ..05). The 3 groups of antihyperlipidemic drugs have beneficial effects on the erythrocyte deformability index. Only fenofibrate has significant beneficial effects on the fibrinogen levels...
  26. ncbi Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults
    Stephanie Badiou
    Laboratoire de Biochimie des Lipides, Department of Biochemistry, 371 Av du Doyen Gaston Giraud, Hopital Lapeyronie, CHU Montpellier F34295, France
    Atherosclerosis 172:273-9. 2004
    ..This study evaluates the effects of fenofibrate and/or Vitamin E on lipoprotein profile...
  27. ncbi Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study
    Melinda Carrington
    Baker Heart Research Institute, Melbourne, Victoria, Australia
    Int J Cardiol 127:51-6. 2008
    ..The aim of this study was to determine the impact of fenofibrate therapy on health care costs in middle-aged patients with type II diabetes at high risk of future cardiovascular events...
  28. ncbi Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat
    B Staels
    Laboratorium voor Experimentele Geneeskunde en Endocrinologie, Katholieke Universiteit Leuven, Belgium
    Arterioscler Thromb 12:286-94. 1992
    ..abstract truncated at 250 words)..
  29. ncbi Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation
    Jadwiga Najib
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York 11201, USA
    Clin Ther 24:2022-50. 2002
    ..The 67- and 200-mg micronized capsules can be considered equivalent to the 54- and 160-mg suprabioavailable tablets, respectively...
  30. ncbi Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study
    Jun Sasaki
    Graduate School of Public Health Medicine, International University of Health and Welfare, Fukuoka, Japan
    Clin Ther 24:1614-26. 2002
    ..Fenofibrate lowers serum total cholesterol and triglyceride levels while it elevates serum high-density lipoprotein cholesterol (HDL-C) level...
  31. ncbi Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse
    Karen M Tordjman
    Institute of Endocrinology, Metabolism and Hypertension, Aviv Sourasky Medical Center, Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel
    Hypertension 50:945-51. 2007
    ..They raise the possibility that its activation may aggravate hypertension and hasten atherosclerosis in the context of an activated renin-angiotensin system...
  32. ncbi Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values
    Vasilis Tsimihodimos
    Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece
    J Cardiovasc Pharmacol Ther 9:27-33. 2004
    ..In this context, a number of inflammatory markers have been studied for their ability to predict future cardiovascular events in asymptomatic individuals or patients with established atherosclerotic disease...
  33. ncbi Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
    Michael H Davidson
    Department of Cardiology, Rush University Medical College, 60610, USA
    Clin Cardiol 29:268-73. 2006
    ....
  34. doi Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9
    Sanae Kourimate
    INSERM U915, CHU Hotel Dieu, 9 quai Moncousu, Nantes, France
    J Biol Chem 283:9666-73. 2008
    ..Moreover, this study validates the functional relevance of a combined therapy associating PCSK9 repressors and statins...
  35. ncbi Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance
    Boguslaw Okopien
    Department of Clinical Pharmacology, Medical University of Silesia, Medykow 18, PL 40 752 Katowice, Poland
    J Clin Endocrinol Metab 91:1770-8. 2006
    ..Apart from lowering lipid levels, peroxisome proliferator-activated receptor (PPAR) alpha activators (fibrates) produce many other favorable effects that may contribute to their clinical effectiveness in dyslipidemic and diabetic patients...
  36. ncbi Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight
    E Chaput
    Department of Metabolic Diseases, Laboratoire Fournier, 50, rue de Dijon, Daix, 21121, France
    Biochem Biophys Res Commun 271:445-50. 2000
    ..These results serve to clearly differentiate the metabolic finality of two distinct classes of drugs, as well as their corresponding nuclear receptors, having similar effects on serum triglycerides...
  37. ncbi Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia
    C Iovine
    Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
    Eur J Clin Invest 36:560-5. 2006
    ..The study evaluated the effects of atorvastatin (20 mg d(-1)) vs. fenofibrate (200 mg d(-1)) on post-prandial lipids in type 2 diabetic patients with mixed hyperlipidaemia...
  38. ncbi Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study
    Katsunori Ikewaki
    Division of Cardiology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 11:278-85. 2004
    ..These effects, together with the favorable effect on inflammation, might provide a clinical benefit in hypertriglyceridemic subjects...
  39. ncbi Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X
    B Idzior-Walus
    Collegium Medicum Jagiellonian University, Krakow, Poland, Laboratoires Fournier, Daix, France
    Eur J Clin Invest 30:871-8. 2000
    ..This study investigated the effects of comicronised fenofibrate in patients with dyslipidemia and polymetabolic syndrome X...
  40. ncbi FIELD study
    A Rees
    University Hospital of Wales, Cardiff, UK
    Diabet Med 23:6-12. 2006
  41. ncbi Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension
    Marc Iglarz
    CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada
    Arterioscler Thromb Vasc Biol 23:45-51. 2003
    ..Thus, we investigated in vivo the interaction between PPARs and ET-1 in deoxycorticosterone acetate (DOCA)-salt rats that overexpress vascular ET-1...
  42. ncbi Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study
    Chao Qiang Lai
    Nutrition and Genomics Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington St, Boston, MA 02111, USA
    Arterioscler Thromb Vasc Biol 27:1417-25. 2007
    ..Apolipoprotein A5 (APOA5) is a key determinant of plasma triglyceride (TG) concentrations. Genetic variation at the APOA5 locus could be responsible for some of the observed differences in response to fenofibrate therapy...
  43. ncbi Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France
    Expert Opin Pharmacother 8:1345-52. 2007
    ..Nevertheless, this combination therapy of ezetimibe plus fenofibrate seems particularly useful for patients with a poor response or intolerance to statin monotherapy...
  44. ncbi Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus
    A Hiukka
    Department of Medicine, Division of Cardiology, Helsinki University Hospital and Biomedicum, Haartmaninkatu 8, 00290, Helsinki, Finland
    Diabetologia 50:2067-75. 2007
    ..We explored the changes in VLDL and HDL subspecies during fenofibrate treatment in a statin-free FIELD cohort...
  45. ncbi Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study)
    Heidi T May
    Intermountain Medical Center and LDS Hospital, Salt Lake City, Utah, USA
    Am J Cardiol 101:486-9. 2008
    ..In conclusion, in this trial of mixed dyslipidemic patients with diabetes, combination therapy was more effective in changing a variety of other cardiovascular risk markers...
  46. doi Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people
    Jean Claude Ansquer
    Laboratoires Fournier, Daix, France
    Am J Kidney Dis 51:904-13. 2008
    ..Fenofibrate was associated with increases in serum creatinine concentrations. The effect of short-term fenofibrate treatment on kidney function was investigated in subjects with normal kidney function...
  47. pmc Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Russell Scott
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Diabetes Care 32:493-8. 2009
    ....
  48. ncbi Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men
    Kathryn E Ryan
    The Royal Group of Hospitals, Belfast, UK
    Atherosclerosis 194:e123-30. 2007
    ..These results suggest that treatment with PPAR agonists has potential to reduce the incidence of premature cardiovascular disease associated with obesity...
  49. ncbi PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats
    Tetsuya Toyama
    Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
    Biochem Biophys Res Commun 324:697-704. 2004
    ..PPARalpha ligands have an antifibrotic action in the rat TAA model of liver cirrhosis, probably due to an antioxidant effect of enhanced catalase expression and activity in the liver...
  50. ncbi Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
    Peter H Jones
    Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 95:120-2. 2005
    ..The findings suggest that the use of fenofibrate in combination with statins results in fewer reports of rhabdomyolysis per million prescriptions dispensed than does the use of gemfibrozil...
  51. ncbi Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC
    Hisashi Murakami
    Department of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa Ku, Nagoya 466 8550, Japan
    Biochem Biophys Res Commun 341:973-8. 2006
    ....
  52. ncbi Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism
    Jean Charles Fruchart
    Lipoprotein and Atherosclerosis Research Unit, INSERM Unité de Recherche sur l Arthérosclérose and Lille University 2 U545, Pasteur Institute of Lille, Lille, France
    Drugs Today (Barc) 42:39-64. 2006
    ..PPARs are also expressed in atherosclerotic lesions...
  53. ncbi Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)
    Jean Claude Ansquer
    Department of Clinical Research and Medical Affairs, Fournier Pharma, Daix, France
    Am J Kidney Dis 45:485-93. 2005
    ..The aim of this analysis is to study the influence of the treatment on changes in urinary albumin excretion...
  54. ncbi Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia
    James M McKenney
    National Clinical Research Inc, Richmond, Virginia 23294, USA
    J Am Coll Cardiol 47:1584-7. 2006
    ..This study sought to determine the long-term safety and efficacy of co-administered fenofibrate (FENO) and ezetimibe (EZE) in patients with mixed hyperlipidemia...
  55. ncbi Effects of fenofibrate on lipid metabolism in adipose tissue of rats
    Adaliene Versiani Matos Ferreira
    Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG 31270 901, Brazil
    Metabolism 55:731-5. 2006
    ..These findings suggest that besides its effects on liver, fenofibrate exerts effects on lipid metabolism in adipose tissue which may contribute to decreasing adiposity...
  56. ncbi Fenofibrate: metabolic and pleiotropic effects
    Vasilis Tsimihodimos
    Department of Internal Medicine, Medical School, University of Ioannina, 451 10 Ioannina, Greece
    Curr Vasc Pharmacol 3:87-98. 2005
    ..Additionally, in cases of refractory dyslipidaemia, the combination of fenofibrate with statins is a therapeutic option...
  57. ncbi PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans
    Savitha Subramanian
    Endocrinology, Metabolism, and Lipid Research, Dept of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Physiol Endocrinol Metab 291:E1365-71. 2006
    ..These data suggest that PPARalpha activation in humans does not correct insulin resistance induced by glucocorticoids and may adversely affect blood pressure...
  58. ncbi Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia
    Kwang Kon Koh
    Vascular Medicine and Atherosclerosis Unit, Division of Cardiology, Gil Heart Center, Gachon Medical School, 1198 Kuwol dong, Namdong gu, Incheon, Korea 405 760
    Diabetes Care 28:1419-24. 2005
    ..We hypothesize fenofibrate improves endothelial function by enhancing insulin sensitivity...
  59. ncbi Fenofibrate-induced acute cholestatic hepatitis
    Chiu Yung Ho
    Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
    J Chin Med Assoc 67:245-7. 2004
    ..Treatment should be discontinued if alanine aminotransferase values increase by more than 100 IU/L...
  60. ncbi Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia
    Warren H Capell
    Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Arterioscler Thromb Vasc Biol 23:307-13. 2003
    ....
  61. ncbi Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS)
    Juha Vakkilainen
    Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
    Circulation 107:1733-7. 2003
    ..We determined whether on-treatment plasma lipid concentrations and LDL particle size contribute to the favorable effect of fenofibrate on the progression of coronary artery disease (CAD)...
  62. ncbi Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
    B Staels
    U325 INSERM, Departement d Atherosclerose, Institut Pasteur, Lille, France
    Nature 393:790-3. 1998
    ....
  63. ncbi Update on fenofibrate
    David R P Guay
    University of Minnesota, College of Pharmacy, Weaver Densford Hall 7 115C, 308 Harvard Street SE, Minneapolis, MN 55455, USA
    Cardiovasc Drug Rev 20:281-302. 2002
    ..The results of other ongoing outcome trials are eagerly awaited. These results will help to establish the overall place of fenofibrate in the hypolipidemic armamentarium...
  64. ncbi Micronized fenofibrate: a new fibric acid hypolipidemic agent
    D R Guay
    Institute for the Study of Geriatric Pharmacotherapy, College of Pharmacy, University of Minnesota, Minneapolis, USA
    Ann Pharmacother 33:1083-103. 1999
    ..To review the efficacy and safety of fenofibrate in the management of hyperlipidemias...
  65. ncbi Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management
    Jutta Dierkes
    Institute of Clinical Chemistry and Biochemistry, University Hospital Magdeburg, Germany
    Drug Saf 26:81-91. 2003
    ....
  66. ncbi Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus
    David A Playford
    University Department of Medicine, The University of Western Australia, Royal Perth Hospital, Perth, Australia
    Am J Cardiol 90:1254-7. 2002
  67. ncbi De novo expression of uncoupling protein 3 is associated to enhanced mitochondrial thioesterase-1 expression and fatty acid metabolism in liver of fenofibrate-treated rats
    Antonia Lanni
    Department of Life Sciences, Second University of Naples, Caserta, Italy
    FEBS Lett 525:7-12. 2002
    ..The data demonstrate that UCP3 is involved in fatty acid utilization and support the notion that UCP3 and MTE-1 are linked within the same metabolic pathway...
  68. ncbi Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia
    D N Kiortisis
    Department of Internal Medicine, Medical School, University of Ioannina, Greece
    Eur J Clin Pharmacol 56:631-5. 2000
    ..We undertook this study to assess the efficacy of fenofibrate in combination with atorvastatin in patients with severe mixed dyslipidemia...
  69. ncbi Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy
    T Stulc
    Third Department of Internal Medicine, Charles University, Prague, Czech Republic
    Nutrition 17:721-3. 2001
    ..We investigated the hypothesis that concomitant treatment with fenofibrate and folic acid leads to a smaller increase in plasma total homocysteine levels than treatment with fenofibrate alone...
  70. ncbi Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia
    M Sebestjen
    Department of Angiology, Hospital of Internal Medicine, University Clinical Centre, Ljubljana, Slovenia
    J Intern Med 251:77-85. 2002
    ..The aim of this study was to compare the effects of cerivastatin and fenofibrate on endothelium dependent and independent arterial dilation...
  71. ncbi A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration
    Patrick Maison
    Service de Pharmacologie Clinique, Hopital Henri Mondor, AP HP, 94010 Creteil Cedex, France
    Atherosclerosis 160:155-60. 2002
    ..In conclusion, fibrates in contrast with statins may combine lipid-lowering with a beneficial effect on fibrinogen. This effect is independent of changes in cholesterol and triglyceride concentrations...
  72. ncbi Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome
    Gloria Lena Vega
    The Center for Human Nutrition, Department of Clinical Nutrition, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9052, USA
    Am J Cardiol 91:956-60. 2003
    ..Therefore, a combination of simvastatin 10 mg/day and fenofibrate 200 mg/day appears to be effective and safe for the treatment of atherogenic dyslipidemia in combined hyperlipidemia...
  73. ncbi Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia
    P Giral
    Service d Endocrinologie Métabolisme, Centre de Détection et de Prévention de l Athérosclérose, Groupe Hospitalier Pitié, Salpetriere, 47 83 boulevard de l Hopital, 75651 Cedex 13, Paris, France
    Atherosclerosis 154:421-7. 2001
    ..We compared the effect of a statin and a fibrate (atorvastatin and fenofibrate) on plasma levels of homocysteine and other thiol compounds in hyperlipidemic patients...
  74. ncbi Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect
    Christiane Legendre
    Laboratoires Fournier, 50 Rue de Dijon, 21121 Daix, France
    Biochem Biophys Res Commun 295:1052-6. 2002
    ..While awaiting corroboration in human, our results suggest that the extent and mechanism of the increase in total Hcy in patients treated with fenofibrate should not a priori be associated with relevant risk...
  75. ncbi Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle
    M Furuhashi
    Second Department of Internal Medicine, Sapporo Medical University School of Medicine, S 1, W 16, Chuo Ku, Sapporo 060 8543, Japan
    J Endocrinol 174:321-9. 2002
    ....
  76. ncbi Fenofibrate increases creatininemia by increasing metabolic production of creatinine
    Carine Hottelart
    Department of Nephrology, CHU Amiens, France
    Nephron 92:536-41. 2002
    ..Fenofibrate-induced increase of daily creatinine production is neither readily explained by accelerated muscular cell lysis. It is proposed that fenofibrate increases the metabolic production rate of creatinine...
  77. ncbi Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration
    Otto Mayer
    Dept of Internal Medicine, Charles University, Medical Faculty, 13 E Benese St, 320 00 Pilsen, Czech Republic
    Eur J Clin Pharmacol 59:367-71. 2003
    ..In our study we aimed to find out whether the folate co-administration would modify the fibrate-induced elevation of tHcy...
  78. ncbi Fenofibrate for patients with asymptomatic primary biliary cirrhosis
    Kazufumi Dohmen
    Department of Internal Medicine, Okabe Hospital, 1 2 1 Myojinzaka Umi machi Kasuya gun Fukuoka 811 2122 Japan
    World J Gastroenterol 10:894-8. 2004
    ..The aim of this study was to examine the safety and efficacy of fenofibrate, a member of the fibrate class of hypolipidemic and anti-inflammatory agent via peroxysome proliferatory-activated receptor alpha, in patients with aPBC...
  79. ncbi Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes
    David A Playford
    Department of Medicine, University of Western Australia, Royal Perth Hospital, GPO Box X2213, WA 6847, Australia
    Atherosclerosis 168:169-79. 2003
    ....
  80. ncbi Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia
    J C Adkins
    Adis International Limited, Auckland, New Zealand
    Drugs 54:615-33. 1997
    ..Further studies are required to determine whether the lipid changes achieved with micronised fenofibrate result in a reduction in cardiovascular morbidity and mortality...
  81. ncbi Fenofibrate treatment in patients with primary biliary cirrhosis
    Hiromasa Ohira
    Am J Gastroenterol 97:2147-9. 2002
  82. ncbi Hypolipidemic mechanisms of Ananas comosus L. leaves in mice: different from fibrates but similar to statins
    Weidong Xie
    Laboratory of Life Sciences and Marine Biology, Life Sciences Division, Graduate School at Shenzhen, Tsinghua University, Shenzhen, China
    J Pharmacol Sci 103:267-74. 2007
    ..Its action mechanisms differentiate from those with fibrates but may be partly similar to those with statins. It is hopeful that AC may serve as the adjuvant for fibrates...
  83. ncbi Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study
    Alvaro Insua
    Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina
    Endocr Pract 8:96-101. 2002
    ..To compare the hypolipidemic effects of gemfibrozil and micronized fenofibrate in patients with primary hyperlipoproteinemia, phenotypes IIa and IIb, with emphasis on their cholesterol-lowering effectiveness...
  84. ncbi Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure
    Volodymyr Labinskyy
    Department of Physiology, New York Medical College, Valhalla, NY 10595, USA
    J Pharmacol Exp Ther 321:165-71. 2007
    ..S. versus control). Thus, preventing changes in myocardial substrate metabolism in the failing heart causes a modest improvement of cardiac function during the progression of the disease, with no effects on the onset of decompensation...
  85. ncbi The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate
    Dimitrios S Christidis
    Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
    J Cardiovasc Pharmacol Ther 11:211-21. 2006
    ....
  86. ncbi Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease
    Xue Zhi Hong
    Institute of Chinese Herb Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, PR China
    Clin Exp Pharmacol Physiol 34:27-35. 2007
    ..However, the side-effects of fenofibrate and the underlying constituents of xuezhikang need to be determined and investigated further...
  87. ncbi Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients
    Diane Brisson
    Community Genomic Medicine Centre, University of Montreal, Chicoutimi Hospital, Quebec, Canada
    Pharmacogenetics 12:313-20. 2002
    ..This study suggests that frequent genetic variations in genes encoding proteins involved in TG-rich lipoprotein metabolism could modulate the response to fenofibrate treatment, as defined in clinical guidelines...
  88. ncbi A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients
    Isabelle Lemieux
    Lipid Research Center, CHUL Research Center, Quebec, Sainte Foy, Canada
    Atherosclerosis 162:363-71. 2002
    ....
  89. ncbi The hypolipidaemic activity of aqueous Erica multiflora flowers extract in Triton WR-1339 induced hyperlipidaemic rats: a comparison with fenofibrate
    Hicham Harnafi
    Laboratoire de Biochimie, Faculty of Sciences, Oujda, Morocco
    J Ethnopharmacol 109:156-60. 2007
    ....
  90. ncbi Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    JAMA 297:1362-73. 2007
    ..Fibrates are weak agonists of peroxisome proliferator-activated receptor alpha (PPAR-alpha). No trials have reported effects of more potent and selective agents...
  91. ncbi The role of fenofibrate in clinical practice
    Alberto Zambon
    Centre for Atherosclerosis Prevention and Treatment, Department of Medicine, Policlinico Universitario, Via Giustiniani 2, 35128 Padua, Italy
    Diab Vasc Dis Res 4:S15-20. 2007
    ..Data are awaited from the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) study to evaluate the outcome benefits of this approach...
  92. ncbi Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs
    Shunji Kasai
    Vitamin E Information and Technology Section, Eisai Co Ltd, 1 3 Tokodai 5 chome, Tsukuba, Ibaraki, Japan
    J Pharmacol Sci 108:40-8. 2008
    ....
  93. ncbi Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus
    Steven G Terra
    Pfizer Global Research and Development, Groton, Connecticut, USA
    Am J Cardiol 102:434-9. 2008
    ..In conclusion, CP-778,875 2 mg/day significantly increased HDL cholesterol, significantly lowered fasting triglycerides, and increased apoA-I and HDL subfractions. The clinical relevance of the increase in homocysteine levels is unknown...
  94. pmc Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome
    Dick C Chan
    Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    Arterioscler Thromb Vasc Biol 28:1831-7. 2008
    ..Disturbed apolipoprotein (apo) C-III metabolism may account for dyslipidemia in these subjects. Atorvastatin and fenofibrate decrease plasma apoC-III, but the underlying mechanisms are not fully understood...
  95. ncbi Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin
    Coralie Metais
    EA 4173 ERI 22 agressions vasculaires et réponses tissulaires, Faculté Rockefeller, UCBLyon1, 69008 Lyon, France
    Metabolism 57:946-53. 2008
    ..Parts of the actions of fenofibrate and of metformin could be mediated by a stimulation of the expression of these receptors in liver and in insulin-sensitive, glucose-utilizing tissues (muscle, WAT), respectively...
  96. doi Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study
    Pierre Landry
    J Clin Psychopharmacol 28:348-9. 2008
  97. ncbi Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
    Eliot A Brinton
    Cardiovascular Genetics, University of Utah School of Medicine, 420 Chipeta Way, Room 1160, Salt Lake City, UT 84108, USA
    Curr Atheroscler Rep 10:25-32. 2008
    ..This review provides an update on the benefits and risks of fibrate monotherapy and addresses the benefits and risks of adding fibrates to statins...
  98. pmc Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects
    Fahim Abbasi
    Stanford University School of Medicine, Stanford, CA, USA
    Am J Cardiol 102:64-9. 2008
    ..In conclusion, there did not appear to be 1 therapeutic intervention that effectively treated all metabolic abnormalities present in these patients at greatly increased risk of cardiovascular disease...
  99. ncbi Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice
    Si Yuan Pan
    Department of Pharmacology, Beijing University of Chinese Medicine, Beijing 100102, China
    J Pharm Pharmacol 59:1657-62. 2007
    ..The results indicate that bicyclol treatment can invariably decrease hepatic lipid levels and increase serum triglyceride levels in normal and hypercholesterolaemic mice...
  100. ncbi Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation
    Y Andersson
    U325 INSERM, Departement d Atherosclerose, Institut Pasteur de Lille et Faculté de Pharmacie, Universite de Lille II, Lille, France
    Arterioscler Thromb Vasc Biol 19:115-21. 1999
    ....
  101. pmc Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment
    Melanie G Cree
    Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, Galveston, TX 77555, United States
    Mech Ageing Dev 128:558-65. 2007
    ..2+/-0.05, insulin resistant). Furthermore, there was no change in IMCL or LFAT. These results indicate that whereas fenofibrate significantly lowers plasma lipids it neither affects insulin sensitivity nor intracellular lipids in elderly...

Research Grants79

  1. Endogenous Mechanisms of PPAR Modulation
    Jorge Plutzky; Fiscal Year: 2005
    ..Together, these studies integrate biochemical, biologic, and in vivo models to better understand how endogenous modulation of PPAR activity may determine biologic responses. ..
  2. ANTIOXIDANT & HYPERGLYCEMIA INDUCED PROCOAGULANT STATE
    Guenther Boden; Fiscal Year: 2005
    ....
  3. Lipolytic Mechanisms of PPAR Activation
    Jorge Plutzky; Fiscal Year: 2007
    ..Through these programmatic efforts, insight will be gained into lipolysis as a mechanism for selective endogenous PPAR activation, and its distal transcriptional effects. ..
  4. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 2007
    ..The hypothesis tested is that apoE-mediated cholesterol efflux from macrophages is independent from ABCA1 or SR-B1 mechanisms. ..
  5. Translating Research into Prevention of Diabetes (TRIP Diabetes)
    David Goff; Fiscal Year: 2007
    ....
  6. CARDIOVASCULAR NUTRITION IN MEDICAL EDUCATION
    Scott Grundy; Fiscal Year: 2002
    ..The long term goal is to produce graduates who routinely address nutrition and exercise for cardiovascular health with their patients. ..
  7. Hyperglycemia and Hyperinsulinemia Induced Procoagulant State
    Guenther Boden; Fiscal Year: 2010
    ....
  8. Modeling of Lung HIV Cytokine/Chemokine Networks
    Paul Skolnik; Fiscal Year: 2006
    ..Identification of the most central molecules in these linked systems may suggest new therapeutic or vaccine approaches to bolster the host immune response to HIV. ..
  9. Personal Digital Assistant for Guideline Adherence Trial
    David Goff; Fiscal Year: 2006
    ..Hence, this innovative strategy holds great promise for making a substantial public health impact through the prevention of CVD and through subsequent translation to other important conditions. ..
  10. New York University HIV/AIDS Clinical Trial Unit
    Judith Aberg; Fiscal Year: 2007
    ..Our unit has given significant scientific contributions to the concept and design of many studies and will continue to do so. ADMINISTRATIVE COMPONENT: ..
  11. Training Program in Host Pathogen Interactions
    Paul Skolnik; Fiscal Year: 2006
    ..abstract_text> ..
  12. Fat Induced Insulin Resistance and Atherosclerosis
    Guenther Boden; Fiscal Year: 2006
    ..We believe that these studies will provide important new information relative to the mechanism by which obesity and FFAs cause IR and ASVD in human subjects. ..
  13. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 2006
    ..The hypothesis tested is that apoE-mediated cholesterol efflux from macrophages is independent from ABCA1 or SR-B1 mechanisms. ..
  14. Lipolytic Mechanisms of PPAR Activation
    Jorge Plutzky; Fiscal Year: 2006
    ..Through these programmatic efforts, insight will be gained into lipolysis as a mechanism for selective endogenous PPAR activation, and its distal transcriptional effects. ..
  15. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2005
    ..These studies have the potential to uncover the basis for the therapeutic effect of HDL on the arterial plaque. ..
  16. Personal Digital Assistant for Guideline Adherence Trial
    David Goff; Fiscal Year: 2005
    ..Hence, this innovative strategy holds great promise for making a substantial public health impact through the prevention of CVD and through subsequent translation to other important conditions. ..
  17. Modeling of Lung HIV Cytokine/Chemokine Networks
    Paul Skolnik; Fiscal Year: 2005
    ..Identification of the most central molecules in these linked systems may suggest new therapeutic or vaccine approaches to bolster the host immune response to HIV. ..
  18. Risk of Type 1 and Type 2 Diabetes among Young Finns
    Jaakko Tuomilehto; Fiscal Year: 2005
    ..The detailed epidemiological data obtained in this study will also lay a foundation for further research of etiological factors, genetic and environmental, predisposing to DMI and DM2 in this age group. ..
  19. Osteoprotegerin and osteopontin in aortic aneurysm
    Jonathan Golledge; Fiscal Year: 2005
    ..Understanding the role of these calcium-controlling proteins in artery weakness and how drug therapy can interfere in these effects is an important step in the development of new treatment for aortic aneurysm. ..
  20. Fat Induced Insulin Resistance and Atherosclerosis
    Guenther Boden; Fiscal Year: 2005
    ..We believe that these studies will provide important new information relative to the mechanism by which obesity and FFAs cause IR and ASVD in human subjects. ..
  21. Free Fatty Acids and Hepatic Insulin Resistance
    Guenther Boden; Fiscal Year: 2007
    ..These studies will hopefully provide much needed information relative to important details and mechanisms of FFA induced hepatic insulin resistance. [unreadable] [unreadable]..
  22. Hyperglycemia and Hyperinsulinemia Induced Procoagulant State
    Guenther Boden; Fiscal Year: 2009
    ....
  23. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 2010
    ..We have discovered a functional connection between two proteins (apoE and LRP1) that improves cholesterol disposal in plaque macrophages, and may lead to development of new drugs for regression of coronary plaques. ..
  24. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 2009
    ..We have discovered a functional connection between two proteins (apoE and LRP1) that improves cholesterol disposal in plaque macrophages, and may lead to development of new drugs for regression of coronary plaques. ..
  25. Hyperglycemia and Hyperinsulinemia Induced Procoagulant State
    Guenther Boden; Fiscal Year: 2009
    ....
  26. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 2008
    ..The hypothesis tested is that apoE-mediated cholesterol efflux from macrophages is independent from ABCA1 or SR-B1 mechanisms. ..
  27. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 2008
    ..We have discovered a functional connection between two proteins (apoE and LRP1) that improves cholesterol disposal in plaque macrophages, and may lead to development of new drugs for regression of coronary plaques. ..
  28. Translating Research into Prevention of Diabetes (TRIP Diabetes)
    David Goff; Fiscal Year: 2008
    ....
  29. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2008
    ..These studies have the potential to uncover the basis for the therapeutic effect of HDL on the arterial plaque. [unreadable] [unreadable] [unreadable] [unreadable]..
  30. Training Grant in Quality of Care and Outcomes Research in Cardiovascular Disease
    David Goff; Fiscal Year: 2008
    ....
  31. New York University HIV/AIDS Clinical Trial Unit
    Judith Aberg; Fiscal Year: 2008
    ..Our unit has given significant scientific contributions to the concept and design of many studies and will continue to do so. ADMINISTRATIVE COMPONENT: ..
  32. Hyperglycemia and Hyperinsulinemia Induced Procoagulant State
    Guenther Boden; Fiscal Year: 2007
    ....
  33. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2007
    ..These studies have the potential to uncover the basis for the therapeutic effect of HDL on the arterial plaque. [unreadable] [unreadable] [unreadable] [unreadable]..
  34. Fat Induced Insulin Resistance and Atherosclerosis
    Guenther Boden; Fiscal Year: 2007
    ..We believe that these studies will provide important new information relative to the mechanism by which obesity and FFAs cause IR and ASVD in human subjects. ..
  35. Free Fatty Acids and Hepatic Insulin Resistance
    Guenther Boden; Fiscal Year: 2005
    ..These studies will hopefully provide much needed information relative to important details and mechanisms of FFA induced hepatic insulin resistance. ..
  36. ANTIOXIDANT & HYPERGLYCEMIA INDUCED PROCOAGULANT STATE
    Guenther Boden; Fiscal Year: 2003
    ....
  37. Risk of Type 1 and Type 2 Diabetes among Young Finns
    Jaakko Tuomilehto; Fiscal Year: 2003
    ..The detailed epidemiological data obtained in this study will also lay a foundation for further research of etiological factors, genetic and environmental, predisposing to DMI and DM2 in this age group. ..
  38. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2003
    ..These studies can be expected to delineate the biology of foam cell formation and the importance of cholesterol efflux in atherogenesis. Moreover, these studies may lay the basis for a gene therapy approach to atherosclerosis. ..
  39. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2002
    ..These studies can be expected to delineate the biology of foam cell formation and the importance of cholesterol efflux in atherogenesis. Moreover, these studies may lay the basis for a gene therapy approach to atherosclerosis. ..
  40. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 2003
    ..The hypothesis tested is that apoE-mediated cholesterol efflux from macrophages is independent from ABCA1 or SR-B1 mechanisms. ..
  41. Lung TACE, TNFalpha & TNFR Regulation of HIV Replication
    Paul Skolnik; Fiscal Year: 2002
    ..This hypothesis-driven project will suggest whether anti-TNF or anti-TACE therapies will improve immunologic function and virologic control in HIV-infected persons receiving HAART. ..
  42. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 2002
    ..Finally, in vitro studies will be conducted to assess the role of LRP in the binding and degradation of B-VLDL. ..
  43. FAT MEDIATED INSULIN SECRETION AND DIABETES IN ELDERLY
    Guenther Boden; Fiscal Year: 2002
    ..We hope that this project will help to better understand the mechanisms by which obesity contributes to the development of NIDDM. ..
  44. ANTIOXIDANT & HYPERGLYCEMIA INDUCED PROCOAGULANT STATE
    Guenther Boden; Fiscal Year: 2002
    ....
  45. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2001
    ..These studies can be expected to delineate the biology of foam cell formation and the importance of cholesterol efflux in atherogenesis. Moreover, these studies may lay the basis for a gene therapy approach to atherosclerosis. ..
  46. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 2001
    ..Finally, in vitro studies will be conducted to assess the role of LRP in the binding and degradation of B-VLDL. ..
  47. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 2000
    ..Finally, in vitro studies will be conducted to assess the role of LRP in the binding and degradation of B-VLDL. ..
  48. FAT MEDIATED INSULIN SECRETION AND DIABETES IN ELDERLY
    Guenther Boden; Fiscal Year: 2000
    ..We hope that this project will help to better understand the mechanisms by which obesity contributes to the development of NIDDM. ..
  49. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 1999
    ..Finally, in vitro studies will be conducted to assess the role of LRP in the binding and degradation of B-VLDL. ..
  50. FAT MEDIATED INSULIN SECRETION AND DIABETES IN ELDERLY
    Guenther Boden; Fiscal Year: 1999
    ..We hope that this project will help to better understand the mechanisms by which obesity contributes to the development of NIDDM. ..
  51. FAT MEDIATED INSULIN SECRETION AND DIABETES IN ELDERLY
    Guenther Boden; Fiscal Year: 2003
    ..We hope that this project will help to better understand the mechanisms by which obesity contributes to the development of NIDDM. ..
  52. Personal Digital Assistant for Guideline Adherence Trial
    David Goff; Fiscal Year: 2003
    ..Hence, this innovative strategy holds great promise for making a substantial public health impact through the prevention of CVD and through subsequent translation to other important conditions. ..
  53. Lipolytic Mechanisms of PPAR Activation
    Jorge Plutzky; Fiscal Year: 2005
    ..Through these programmatic efforts, insight will be gained into lipolysis as a mechanism for selective endogenous PPAR activation, and its distal transcriptional effects. ..
  54. Personal Digital Assistant for Guideline Adherence Trial
    David Goff; Fiscal Year: 2003
    ..Hence, this innovative strategy holds great promise for making a substantial public health impact through the prevention of CVD and through subsequent translation to other important conditions. ..
  55. Personal Digital Assistant for Guideline Adherence Trial
    David Goff; Fiscal Year: 2004
    ..Hence, this innovative strategy holds great promise for making a substantial public health impact through the prevention of CVD and through subsequent translation to other important conditions. ..
  56. Risk of Type 1 and Type 2 Diabetes among Young Finns
    Jaakko Tuomilehto; Fiscal Year: 2004
    ..The detailed epidemiological data obtained in this study will also lay a foundation for further research of etiological factors, genetic and environmental, predisposing to DMI and DM2 in this age group. ..
  57. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2004
    ..These studies can be expected to delineate the biology of foam cell formation and the importance of cholesterol efflux in atherogenesis. Moreover, these studies may lay the basis for a gene therapy approach to atherosclerosis. ..
  58. Fat Induced Insulin Resistance and Atherosclerosis
    Guenther Boden; Fiscal Year: 2004
    ..We believe that these studies will provide important new information relative to the mechanism by which obesity and FFAs cause IR and ASVD in human subjects. ..
  59. Innate Immunity, HIV, and OIs: Role of TLRs in the Lung
    Paul Skolnik; Fiscal Year: 2004
    ..The innovation of this grant is a new paradigm that suggests direct or indirect effects of HIV on TLRs that may affect innate immune responses to OIs or HIV, itself. ..
  60. Lipolytic Mechanisms of PPAR Activation
    Jorge Plutzky; Fiscal Year: 2004
    ..Through these programmatic efforts, insight will be gained into lipolysis as a mechanism for selective endogenous PPAR activation, and its distal transcriptional effects. ..
  61. Control of cancer and metastasis by endothelial-derived epoxyeicosatrienoic acids
    Dipak Panigrahy; Fiscal Year: 2010
    ..Conversely, blocking the EET pathway may offer a new strategy to block tumor blood vessels and, hence, help combat cancer. Thus, novel drugs which block EETs will be tested in preclinical trials to confirm their activity. ..
  62. Hyperglycemia and Hyperinsulinemia Induced Procoagulant State
    Guenther Boden; Fiscal Year: 2010
    ....
  63. Osteoprotegerin and osteopontin in aortic aneurysm
    Jonathan Golledge; Fiscal Year: 2009
    ..Understanding the role of these calcium-controlling proteins in artery weakness and how drug therapy can interfere in these effects is an important step in the development of new treatment for aortic aneurysm. ..
  64. ANTIOXIDANT & HYPERGLYCEMIA INDUCED PROCOAGULANT STATE
    Guenther Boden; Fiscal Year: 2004
    ....
  65. FUNCTIONAL HIERARCHY OF REMNANT LIPOPROTEIN RECEPTORS
    Sergio Fazio; Fiscal Year: 2006
    ..The hypothesis tested is that apoE-mediated cholesterol efflux from macrophages is independent from ABCA1 or SR-B1 mechanisms. ..
  66. Osteoprotegerin and osteopontin in aortic aneurysm
    Jonathan Golledge; Fiscal Year: 2008
    ..Understanding the role of these calcium-controlling proteins in artery weakness and how drug therapy can interfere in these effects is an important step in the development of new treatment for aortic aneurysm. ..
  67. Hyperglycemia and Hyperinsulinemia Induced Procoagulant State
    Guenther Boden; Fiscal Year: 2008
    ....
  68. Personal Digital Assistant for Guideline Adherence Trial
    David Goff; Fiscal Year: 2002
    ..Hence, this innovative strategy holds great promise for making a substantial public health impact through the prevention of CVD and through subsequent translation to other important conditions. ..
  69. Osteoprotegerin and osteopontin in aortic aneurysm
    Jonathan Golledge; Fiscal Year: 2006
    ..Understanding the role of these calcium-controlling proteins in artery weakness and how drug therapy can interfere in these effects is an important step in the development of new treatment for aortic aneurysm. ..
  70. Free Fatty Acids and Hepatic Insulin Resistance
    Guenther Boden; Fiscal Year: 2004
    ..These studies will hopefully provide much needed information relative to important details and mechanisms of FFA induced hepatic insulin resistance. ..
  71. Free Fatty Acids and Hepatic Insulin Resistance
    Guenther Boden; Fiscal Year: 2006
    ..These studies will hopefully provide much needed information relative to important details and mechanisms of FFA induced hepatic insulin resistance. [unreadable] [unreadable]..
  72. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2006
    ..These studies have the potential to uncover the basis for the therapeutic effect of HDL on the arterial plaque. [unreadable] [unreadable] [unreadable] [unreadable]..
  73. Osteoprotegerin and osteopontin in aortic aneurysm
    Jonathan Golledge; Fiscal Year: 2007
    ..Understanding the role of these calcium-controlling proteins in artery weakness and how drug therapy can interfere in these effects is an important step in the development of new treatment for aortic aneurysm. ..